References:
1. Norgren, L., et al., The Next 10 years in the Management of Peripheral Artery Disease: Perspectives from The ‘PAD 2009’ Conference.European Journal of Vascular & Endovascular Surgery, 2010.40 (3): p. 375-380.
2. Norgren, L., et al., Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery, 2007. 45 (1): p. S5-S67.
3. Varu, V.N., M.E. Hogg, and M.R. Kibbe, Critical limb ischemia.Journal of Vascular Surgery, 2010. 51 (1): p. 230-241.
4. Bradbury, A.W., et al., Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. Journal of Vascular Surgery, 2010. 51 (5): p. 18S-31S.
5. Santema, T.B., et al., Not All Patients with Critical Limb Ischaemia Require Revascularisation. European journal of vascular and endovascular surgery, 2016. 53 (3): p. 371-379.
6. Benoit, E., et al., Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement. Journal of Vascular Surgery, 2012. 55 (3): p. 781-789.
7. Mohamed, S.A., et al., Autologous bone marrow mesenchymal stromal cell therapy for ”no-option” critical limb ischemia is limited by karyotype abnormalities. Cytotherapy, 2020. 22 (6): p. 313-321.
8. Abu Dabrh, A.M., et al., The natural history of untreated severe or critical limb ischemia. Journal of vascular surgery, 2015.62 (6): p. 1642-1651.e3.
9. Steunenberg, S.L., et al., Quality of Life and Traditional Outcome Results at 1 Year in Elderly Patients Having Critical Limb Ischemia and the Role of Conservative Treatment. Vasc Endovascular Surg, 2020. 54 (2): p. 126-134.
10. Thomas, A.R., et al., Conservative Treatment in Selected Patients with Severe Critical Limb Ischemia. World Journal of Surgery, 2015. 39 (8): p. 2090-2095.
Table 1: Demographic data and patient’s characteristics